Vor Biopharma (NASDAQ:VOR) Shares Up 7.2% – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price was up 7.2% on Thursday. The company traded as high as $20.02 and last traded at $20.0950. Approximately 122,578 shares were traded during trading, a decline of 88% from the average daily volume of 1,057,865 shares. The stock had previously closed at $18.75.

Wall Street Analyst Weigh In

VOR has been the topic of a number of recent analyst reports. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wedbush lifted their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Vor Biopharma Stock Up 4.3%

The company has a fifty day moving average of $21.77 and a two-hundred day moving average of $18.34.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Analysts predict that Vor Biopharma Inc. will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VOR. Engineers Gate Manager LP boosted its stake in shares of Vor Biopharma by 37.5% during the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after acquiring an additional 10,071 shares during the period. Braidwell LP grew its holdings in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after purchasing an additional 106,330 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Vor Biopharma in the 2nd quarter worth approximately $499,000. Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma during the 2nd quarter valued at $1,799,000. Finally, Bank of America Corp DE raised its holdings in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares during the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.